

I hereby certify that this correspondence is being filed via  
EFS-Web with the United States Patent and Trademark Office  
on 20 Oct 2008

TOWNSEND and TOWNSEND and CREW LLP

By: Malinda Adagat

PATENT  
Attorney Docket No.: 015280-405100US  
Client Ref. No.: DHHS No.: E-293-1999/0-US-06  
Customer No.: 45115

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

LEPLA *et al.*

Application No.: 10/088,952

Filed: March 22, 2002

For: MUTATED ANTHRAX TOXIN  
PROTECTIVE ANTIGEN PROTEINS  
THAT SPECIFICALLY TARGET  
CELLS CONTAINING HIGH  
AMOUNTS OF CELL-SURFACE  
METALLOPROTEINASES OR  
PLASMINOGEN ACTIVATOR  
RECEPTORS

Confirmation No. 4741

Examiner: Fetterolf, Brandon J.

Art Unit: 1642

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

AND

AMENDMENT AFTER ALLOWANCE

UNDER 37 CFR § 1.312

Mail Stop Issue Fee  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In response to the Examiner's telephone request to furnish a Sequence Listing, Applicants submit herewith the required paper copy and computer readable copy of the Sequence Listing. Please amend the specification as follows.

**Amendments to the Specification** begin on page 2 of this paper.

**Remarks** begin on page 3 of this paper.